Rank |
Status |
Study |
1 |
Recruiting
|
Validation of an URTICARIA Control Test
Condition: |
Chronic URTICARIA |
Intervention: |
|
Outcome Measure: |
URTICARIA activity |
|
2 |
Unknown †
|
Evaluating for Contact Allergies in Patients With Chronic URTICARIA
Conditions: |
URTICARIA; Patch Testing; Dermatitis; Allergy; Contact Sensitization |
Intervention: |
Procedure: Patch Testing |
Outcome Measures: |
To identify contact allergens with patch testing in patients with chronic idiopathic URTICARIA living in the New England area.; To determine if avoidance of contact allergens causes the resolution of chronic URTICARIA in those patients with positive patch test results. |
|
3 |
Recruiting
|
Profiling URTICARIA for the Identification of Subtypes
Conditions: |
Non-autoreactive Chronic Spontaneous URTICARIA; Autoimmune Chronic Spontaneous URTICARIA; Autoreactive, Non-autoimmune Chronic Spontaneous URTICARIA |
Intervention: |
|
Outcome Measures: |
Results of the ASST; Results of a cell activating assay (BHRA); Results of autoantibody-test (anti-IgE and anti-FcRI); Results of URTICARIA activity score (UAS7); Results of HRQoL scores (CU-Q2oL, DLQI); Results of laboratory tests (Thyroid antibodies (anti-TPO +/- anti-thyreoglobulin); ANA; Rheumatoid factor; CRP; ESR; total IgE; T3,T4, TSH, diff BB, Helicobacter pylori stool antigen test or breath test; D-Dimer) |
|
4 |
Recruiting
|
Development of an URTICARIA Control Test
Condition: |
Chronic URTICARIA |
Intervention: |
|
Outcome Measure: |
|
|
5 |
Recruiting
|
Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic URTICARIA in Thailand
Conditions: |
Allergic Rhinitis; Non-allergic Rhinitis; Chronic URTICARIA |
Intervention: |
|
Outcome Measures: |
The recalcitrant symptoms of chronic rhinitis or chronic URTICARIA; The correlation between symptom severity and quality of life |
|
6 |
Not yet recruiting
|
Study of the Effects of Chinese Herbal Medicine on Chronic URTICARIA
Condition: |
Chronic URTICARIA |
Interventions: |
Drug: Chinese Herbal Medicine (CHM); Drug: Placebo |
Outcome Measures: |
Changes in symptom severity; Improvement of sleep disturbance; Changes of serologic markers for URTICARIA |
|
7 |
Recruiting
|
Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic URTICARIA (CIU) Antihistamines
Condition: |
Chronic Idiopathic URTICARIA |
Interventions: |
Drug: AZD1981; Drug: Placebo |
Outcome Measures: |
The change in diary-based clinical symptoms as measured by the URTICARIA Activity Score 7 (UAS7); The number of participants with adverse events; The ability of AZD1981 to inhibit PGD2-induced Eosinophil shape; The quality of life benefit provided by treatment of refractory CIU with AZD1981 in CIU as assessed by a sleep interference scale and Dermatology Life Quality Index (DLQI) |
|
8 |
Recruiting
|
Methotrexate in the Treatment of Chronic Idiopathic URTICARIA
Condition: |
Chronic URTICARIA |
Interventions: |
Drug: Methotrexate (Novatrex ®) + anti-H1; Drug: Placebo + anti-H1 |
Outcome Measures: |
Number of patients with complete remission of URTICARIA at 18 weeks; Tolerance : clinical and biological safety; Efficacy of the treatment in improving symptoms : pruritus; Persistency of the complete remission at 26 weeks; Efficacy of the treatment in improving symptoms : outbreaks by week; Efficacy of the treatment in improving symptoms : duration of lesions; Efficacy of the treatment in improving quality of life; Efficacy of the treatment in improving quality of sleep; Efficacy of the treatment in improving facial/cervical URTICARIAl lesions |
|
9 |
Unknown †
|
The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic URTICARIA
Conditions: |
Chronic Idiopathic URTICARIA; URTICARIA |
Intervention: |
Drug: Denosin® and Xyzal® |
Outcome Measures: |
To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the patient diaries during the first two weeks of treatment; To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects’ diaries over the 6 weeks.; To evaluate the reflective average AM/PM scores for number of hives, size of largest hive, and total symptom score (sum of pruritus, number of hives, and size of largest hive scores).; Average individual AM/PM instantaneous scores for pruritus, number of hives, and size of largest hive are also evaluated.; AM instantaneous scores for pruritus, number of hives, and size of largest hive are also evaluated.; PM instantaneous scores for pruritus, number of hives, and size of largest hive are also evaluated.; PM reflective scores for pruritus, number of hives, and size of largest hive are also evaluated.; The interference with sleep (AM reflective), and interference with daily activities (PM reflective) are other secondary efficacy outcomes. |
|
10 |
Recruiting
|
Dietary Treatment for Chronic URTICARIA
Conditions: |
Diet Modification; Chronic URTICARIA |
Interventions: |
Other: Treatment group (on low histamine diet); Other: Well-balanced diet |
Outcome Measures: |
The change in Mean Total Symptoms Score (MTSS) from baseline between groups; the change in mean pruritus score (MPS) between treatment group and control group; the change in mean number of wheals (MNW) between groups; the change in global symptoms severity (GSS) by medical investigator between groups; the comparison of area under the curve (AUC for the trend) for MTSS, MPS, MNW, GSS and DCS between the groups during the 4-week period |
|
11 |
Recruiting
|
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic URTICARIA
Condition: |
Chronic URTICARIA |
Intervention: |
Drug: Omalizumab |
Outcome Measures: |
Change in the basophil proteome; Change in basophil proteome in responders to omalizumab compared to non-responders to omalizumab |
|
12 |
Recruiting
|
Pathogenesis of Physical Induced URTICARIAl Syndromes
Conditions: |
Autoinflammatory Syndromes; Physical URTICARIA |
Intervention: |
|
Outcome Measure: |
|
|
13 |
Recruiting
|
Efficacy Study of Omalizumab in Cholinergic URTICARIA
Condition: |
Cholinergic URTICARIA |
Interventions: |
Biological: Active; Biological: Placebo; Biological: Open labeled |
Outcome Measures: |
Negativization of the exercise challenge test; Quality of life; Patients' card; Treatment drop offs in each sequence |
|
14 |
Recruiting
|
T Cell Function in Chronic Idiopathic URTICARIA
Condition: |
Chronic URTICARIA |
Intervention: |
|
Outcome Measure: |
|
|
15 |
Recruiting
|
Cold URTICARIA Treatment With Xolair
Condition: |
Cold Contact URTICARIA |
Interventions: |
Drug: Omalizumab; Drug: Placebo |
Outcome Measures: |
Change in critical temperature thresholds (CTT) from baseline to day 70 after treatment with omalizumab compared to placebo; Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting |
|
16 |
Recruiting
|
Efficacy Study of Canakinumab to Treat URTICARIA
Condition: |
Chronic Idiopathic URTICARIA |
Interventions: |
Drug: Canakinumab; Drug: Placebo |
Outcome Measure: |
Complete clinical remission |
|
17 |
Unknown †
|
The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic URTICARIA and/or Angioedema
Conditions: |
URTICARIA; Angioedema |
Intervention: |
Behavioral: Dietary Therapy |
Outcome Measures: |
The frequency and severity of CIU and/or angioedema (as determined via a five point rating scale); The relative use of antihistamines (ie how many, how often) |
|
18 |
Recruiting
|
Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute URTICARIA Associated With an Acute Allergic Reaction.
Condition: |
Acute URTICARIA |
Interventions: |
Drug: JDP-205 Injection; Drug: Diphenhydramine |
Outcome Measure: |
Change of Extent of URTICARIA symptom score |
|
19 |
Not yet recruiting
|
Platelet Activation in Chronic Inflammatory Skin Diseases
Conditions: |
URTICARIA; Atopic Dermatitis |
Intervention: |
Procedure: Blood sampling |
Outcome Measures: |
Platelet activation; Mean platelet volume |
|
20 |
Recruiting
|
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: |
Nervous System Malformations; Arthropathy, Neurogenic; URTICARIA; Papilledema |
Intervention: |
|
Outcome Measure: |
Comparison of group mean of total disease diary score before compared to after treatment (3-4 mo); mean change in the area under the curve in SAA in patients before and 3-4 mo after tx as well as before and after drug withdrawal. |
|